



OBEGLUTIDE ®

viholabs
Outstanding
OTX solutions



OBEGLUTIDE® Spray is an optimized nutraceutical, designed to:

- enhance nutrient absorption,
- convert fat to energy, and
- regulate appetite.

It also improves mood by boosting serotonin levels and reducing cortisol.

It is safer, easier to administer, and has a better price, with an important differential value compared to potential competitors.

OBEGLUTIDE®



viho**labs**
Outstanding
OTX solutions

SynchroAxis® Technology

SynchroAxis® is an innovative technological system during the manufacturing process that **optimizes the effectiveness, bioavailability and safety of the active ingredients**, based on the concept patented by VihoLabs of **Optimized Dynamic Unicity**.

240 sprays = 1.200 pills




Effects

- **Appetite and Fat Reduction:**
 - Stimulates GLP1, CCK, and Leptin secretion, improving sensitivity to them.
 - Increases the feeling of satiety.
 - Helps eliminate accumulated localized fat, reducing body volume, without loss of muscle mass.
- **Metabolic and Energy Enhancement:**
 - Enhances the efficiency of the body's cells in the glucose metabolism process.
 - Raises energy levels.
- **Stress and Mood Improvement:**
 - Reduces cortisol levels, promoting stress control.
 - Stimulates the secretion of serotonin, improving mood.


Advantages

- Its bioavailability is 20% higher than other solutions thanks to our SynchroAxis Technology.
- It is more effective than other solutions even at lower doses.
- It is safer and without the adverse effects of the most used treatments.
- It can be used discreetly everywhere thanks to its easily transportable packaging.


- Increases the levels of **GLP-1**, **leptin** and **CCK**, which regulate, among other things, the desire to eat and appetite, as well as slow intestinal transit, **giving a feeling of satiety**.



- **Reduces the levels of fat circulation**, preventing the consequent storage and generation of fat. **Helps eliminate fat and regulate glucose levels.**
- **Reduces body volume** by burning and mobilizing accumulated fat, **without loss of muscle mass.**
- **Increases energy levels** and stimulates the nervous system. High energy levels help people to be **more active** during the day, which definitely **helps with weight loss.**



- **Increases serotonin levels naturally** which helps **control mood**. When serotonin levels are high, it's easier to **avoid cravings**.





VS





VS



Product	Dosage	Dosage Form	Approved for	Patient	Other Benefits	Adverse effects
Ozempic (Semaglutide)	1 weekly		Type 2 Diabetes		Heart, Kidneys, weight loss	Nausea Diarrhea Vomiting Headache Psychological problems Suicide
Rybelsus (Semaglutide)	1 Daily		Type 2 Diabetes		Heart, Kidneys, weight loss	
Wegovy (Semaglutide)	1 weekly		Weight Loss		Weight loss	
Trulicity (Dulaglutide)	1 weekly		Type 2 Diabetes		N/A	
Victoza (Liraglutide)	1 Daily		Type 2 Diabetes		Heart, Kidneys, weight loss	
Saxenda (Liraglutide)	1 Daily		Weight Loss		Heart, Kidneys, weight loss	
Byetta (Exenatide)	2 Daily		Type 2 Diabetes		N/A	
Bydureon BCise (Exenatide)	1 weekly		Type 2 Diabetes		Weight loss	
Mounjaro (Tirzepatide)	1 weekly		Type 2 Diabetes		Weight loss	
OBE GLU TIDE	1 Daily		Diabesity		Weight loss	N/A



Clinical study available



Patients	Women	Men
21	13	8




Average Initial Weight	Average Final Weight	Weight Difference
85.87Kg	80.45Kg	5.42Kg



OBEGLUTIDE® Spray combined with a diet it can help you lose 5.42 kg in just 4 weeks of treatment, that is, 24.68% more effective than following the diet alone. - Results of the San Francisco Clinic study, Ciudad Real, 2017.



VS



* p<0.05



Unveiling a Superior Solution for Weight Management

OBEGlutide® SPRAY

Therapeutic Advantages

Mechanism of Action:

GLP-1 Agonists: Synthetically occupy the natural GLP-1 receptors, which can reduce their efficacy and cause a series of adverse effects. This mechanism can result in inefficient system performance, similar to what is observed with corticosteroids.

OBEGLOTIDE: Stimulates the production of GLP-1 without replacing its natural function. Enhances system function without causing atrophy.

Scope of Action:

GLP-1 Agonists: Do not act on other factors involved in obesity and overweight.

OBEGLOTIDE: Acts comprehensively on the main causes of obesity, increasing levels of CCK and leptin, which actively participate in satiety, in addition to improving mood and energy.

Effect on Visceral Fat:

GLP-1 Agonists: Do not act on localized visceral fat, also that between 20% and 40% of Overall weight loss may come from loss of muscle mass . [\[1,2,3\]](#)

OBEGlutide: Directly reduces visceral fat and do not loss muscle mass.

Side Effects:

GLP-1 Agonists: Can cause mood-related side effects, including suicidal thoughts, and other significant adverse effects on the thyroid. [\[4,5,6,7,8,9\]](#)

OBEGlutide: Improves patients' mood and vitality, with no reported adverse side effects.

Rebound Effect:

GLP-1 Agonists: Have a significant rebound effect when administration is stopped, with patients regaining weight or more, likely because the GLP-1 system has been atrophied. [\[10,11,12\]](#)

OBEGlutide: Does not have a rebound effect.

Usage Advantages

Method of Administration:

GLP-1 Agonists: Generally administered via injections, which can be painful..

OBEGLOTIDE: Is an oral spray, easy to carry anywhere.

Adjustment of Treatment and Diet:

GLP-1 Agonists: Difficult to adjust in treatment and diet, with problems related to carbohydrates, proteins, and meal frequency. [\[13,14,15\]](#)

OBEGLOTIDE: Easy to adjust to the patient's habits.

Competitive Advantages

Availability:

GLP-1 Agonists: Frequently out of stock.

OBEGlutide: Has no availability issues, providing a window of opportunity created by current market shortages.

Cost:

GLP-1 Agonists: Costly and Exclusive.

OBEGlutide: Affordable and Accessible.

Scientific references:

1. Researchers from several academic and clinical centers, "Once-weekly semaglutide in overweight or obese adults," New England Journal of Medicine, 2021. DOI: 10.1056/NEJMoa2032183. This study found that patients taking semaglutide experienced a decrease in lean mass, suggesting a loss of muscle along with loss of body fat. <http://www.nejm.org/doi/full/10.1056/NEJMoa2032183>
2. Jay Backstrom et al., "Addressing muscle loss associated with the use of GLP-1 medications," Pharma News Intelligence, April 2, 2024. This article reviews studies showing that between 20% and 40% of Overall weight loss may come from loss of muscle mass in patients using GLP-1 agonists. <https://pharmanewsintel.com/news/addressing-muscle-loss-associated-with-glp-1-medication-use>
3. Multiple researchers from the National Health System (SNS), "Semaglutide versus GLP-1 agonists. Efficacy, safety and quality of life in patients with diabetes mellitus 2. VARIOS study", consulted in 2024. This study compares the loss of weight and lean mass in patients treated with semaglutide and other GLP-1 agonists, indicating that loss of muscle mass is an observed effect. https://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1134-928X2022000200056
4. Suicidal thoughts and self-harm: The European Medicines Agency (EMA) is reviewing data on the risk of suicidal thoughts and self-harm with medications known as GLP-1 receptor agonists, including Ozempic (semaglutide), Saxenda (liraglutide) and Wegovy (semaglutide). This review was prompted by reports of suicidal thoughts and self-harm in people using liraglutide and semaglutide. Around 150 reports of possible cases of self-harm and suicidal thoughts have been recovered and analyzed so far, although it is not yet clear whether the reported cases are directly related to the medications or to the patients' underlying conditions (European Medicines Agency). <https://www.ema.europa.eu/en/news/ema-statement-ongoing-review-glp-1-receptor-agonists>
5. FDA investigation: The US Food and Drug Administration (FDA) is also evaluating reports related to suicidal ideation in patients taking GLP-1 receptor agonists. Since 2010, the FDA has received 265 reports of suicidal ideation in patients using these diabetes or weight loss medications. <https://www.tctmd.com/news/glp-1-meds-linked-265-reports-fda-suicidal-ideation>
6. French national study: A comprehensive study using the French health insurance database evaluated the risk of thyroid cancer associated with GLP-1 receptor agonists. The study included 2,562 thyroid cancer cases and 45,184 control subjects. The results indicated an increased risk of thyroid cancer, particularly medullary thyroid cancer, with a hazard ratio (HR) of 1.58 for overall thyroid cancer and 1.78 for medullary thyroid cancer after 1 to 3 years of treatment with GLP-1 receptor agonists. Available at: <http://diabetesjournals.org/care/article/46/5/384/147301/GLP-1-Receptor-Agonists-and-the-Risk-of-Thyroid>
7. Rodent Studies and FDA Concerns: Preclinical studies have shown that GLP-1 receptor agonists can cause C-cell hyperplasia and tumors in the thyroid glands of rodents. This led the US Food and Drug Administration (FDA) to contraindicate the use of certain GLP-1 receptor agonists, such as liraglutide and semaglutide, in patients with a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2. However, the relevance of these findings to humans remains uncertain. Available at: <http://www.tctmd.com/news/glp-1-meds-linked-265-reports-fda-suicidal-ideation>
8. Meta-analysis and observational studies: Several studies have provided mixed results. For example, the LEADER trial reported an increased, but not statistically significant, risk of thyroid cancer with liraglutide. In contrast, a meta-analysis of 12 clinical trials found no significant increase in the risk of thyroid cancer. Furthermore, some observational studies using US databases found a non-significant trend toward increased risk with exenatide (odds ratio 1.46, 95% CI 0.98–2.19). Available at: <http://www.tctmd.com/news/ema-investigating-suicidal-thinking-glp-1-drugs-weight-loss>
9. Systematic reviews and case-control studies: Some recent systematic reviews and case-control studies continue to explore this potential risk. For example, a study published in "Diabetes Care" concluded that data need to be interpreted with caution due to potential confounding factors, such as obesity and other thyroid-related conditions, which were not fully accounted for in some analyses. Available at: <http://www.jwatch.org/na57373/2024/04/25/glp-1-agonists-arent-associated-significantly-with-thyroid>
10. Wilding JP, et al. "The rebound effect after discontinuation of GLP-1 receptor agonists: a narrative review and clinical implications." Diabetes, Obesity and Metabolism, 2016. DOI: 10.1111/dom.12636. Available at: <http://dx.doi.org/10.1111/dom.12636>
11. Schifano F, et al. "GLP-1 Receptor Agonists and Related Mental Health Issues; Insights from a Range of Social Media Platforms Using a Mixed-Methods Approach." Brain Sciences, 2023. DOI: 10.3390/brainsci13111503. Available at: <https://www.mdpi.com/2076-3425/13/11/1503>
12. "Time-dependent effect of GLP-1 receptor agonists on cardiovascular benefits: a real-world study." Cardiovascular Diabetology, 2024. DOI: 10.1186/s12933-023-01667-8. Available at: <https://cardiab.biomedcentral.com/articles/10.1186/s12933-023-01667-8>
13. Lubell J., "In age of GLP-1 agonists, food choices still matter for health," American Medical Association, 2024. Available at: <http://www.ama-assn.org/in-age-of-glp-1-agonists-food-choices-still-matter-for-health>
14. "Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Glp-1 Receptor Agonists: A Multidisciplinary Expert Consensus," Journal of Clinical Medicine, 2023. DOI: 10.3390/jcm12010145. Available at: <http://www.mdpi.com/2077-0383/12/1/145>
15. Jasna Klen, Vita Dolžan, "Glucagon-like Peptide-1 Receptor Agonists in the Management of Type 2 Diabetes Mellitus and Obesity: The Impact of Pharmacological Properties and Genetic Factors," International Journal of Molecular Sciences, 2022. DOI: 10.3390/ijms23073451. Available at: <http://www.mdpi.com/1422-0067/23/7/3451>



Market Opportunities

OBEGLUTIDE® SPRAY

1. Expanding Market Demand:

Global GLP-1 Receptor Agonists Market reached US\$18.75 Billion in 2022 and is projected to reach US\$133.5 Billion by 2030, with a CAGR of 20.6%, between 2020 and 2023. The market is expanding rapidly and seeking effective solutions for obesity and overweight.

"Booming and continuously growing market, it's time to take positions and lead the weight loss revolution."

2. Proven Market Success:

In 2023, sales of Novo Nordisk's Ozempic increased by 23%, reaching approximately €11.6 billion. There is ample growth potential, especially for OBEGLOTIDE, which offers an affordable price for everyone.

"Let's democratize the market: effective solutions within everyone's reach."

3. Supply Shortages:

The ongoing shortages of GLP-1 agonists present a unique opportunity for OBEGLOTIDE to fill this market gap, offering an accessible and consistent solution.

"Don't miss this opportunity: fill the market gap now."

4. Strategic Advantage:

The regulatory simplicity of OBEGlutide allows for a rapid market launch, capitalizing on the current shortages of GLP-1 agonists.

"Quick and easy launch: your advantage in a hungry market."

5. Innovative Solution:

OBEGlutide stands out for its ease of use, needle-free, convenient, and affordable, enabling effective weight management with just five sprays daily.

"You're 5 sprays away from controlling your scale, without hurting you or your wallet."

6. Greater Safety and Efficacy:

OBEGlutide not only offers a safer and more effective approach to reducing the global impact of obesity and overweight but also provides significant advantages over current market leaders.

"Safer, more effective: lose weight happily."

Innovative Solution: OBEGLOTIDE offers a groundbreaking, needle-free, comfortable, and cost-effective product that makes effective weight management accessible with just five sprays a day.

"No pricks, comfortable, affordable, and safe. Just five sprays away from controlling your scale."

Enhanced Safety and Efficacy: OBEGLOTIDE delivers a superior and safer approach to reducing obesity and overweight, providing substantial benefits over current market leaders.

"Achieve your goal without pain, neither to you nor your wallet."

OBEGLOTIDE is revolutionizing weight management with its innovative, user-friendly, and affordable solution. As the market continues to grow and the demand for effective obesity treatments rises, OBEGLOTIDE stands out with its unique benefits and strategic advantages.

"Lead the weight loss revolution in your market with OBEGLOTIDE—effective, safe, and within everyone's reach."

No pricks, comfortable, affordable, and safe.

OBEGLUTIDE®

Just five sprays away from
controlling your scale.

Product	Application
Semaglutide	
Dulaglutide	
Liraglutide	
Exenatide	
Tirzepatide	
Obeglutide	

"Achieve your goal, without pain,
neither to you nor your wallet."

viholabs
Outstanding
OTX solutions



Your Call!

Join this revolution and lead the market or watch from the sidelines.

Choose to succeed.

Choose to join

